Ramesh Bhandari

Dr. Ramesh Bhandari

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
Raushan Kumar ChaudharyRaushan Kumar Chaudhary
Raushan Kumar Chaudhary
MPMelwin Johns Philip
Melwin Johns Philip
ASAshly Santhosh
Ashly Santhosh
SKSatish S. Karoli
Satish S. Karoli
RBRamesh Bhandari
Ramesh Bhandari
MGM.S. Ganachari
M.S. Ganachari

10 February 2022 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
Raushan Kumar ChaudharyRaushan Kumar Chaudhary
Raushan Kumar Chaudhary
SKSatish S. Karoli
Satish S. Karoli
PDPrarambh S R Dwivedi
Prarambh S R Dwivedi
RBRamesh Bhandari
Ramesh Bhandari

21 December 2020 in Clinical Epidemiology and Global Health
Verified
Journal Article
Open access
AHAishwarya C. Hiremath
Aishwarya C. Hiremath
RBRamesh Bhandari
Ramesh Bhandari
SWShashikala Wali
Shashikala Wali
MGM.S. Ganachari
M.S. Ganachari
BDBhavana Doshi
Bhavana Doshi
Background: Psoriasis is a chronic inflammatory disease and requires long term management due to which patients become non-adherent to the therapy. Hence this study aims to assess the impact of clinical pharmacists to improve medication adherence in patients with psoriasis. Materials and methods This is a randomized controlled study conducted at a tertiary care teaching hospital in the dermatology department, among 68 patients. Aged 18–65 years from the outpatient department diagnosed with psoriasis disease and on treatment were enrolled in the study. Patients with multiple co-morbidities like HIV, hepatitis B/C, and vulnerable populations like lactating and pregnant women are excluded from the study. Enrolled patients are then randomized after taking the Informed consent form. The interventional groups of patients were provided with a patient information leaflet and pharmacist education and counselling along with standard care. Medication adherence of the patients was evaluated at the baseline level to the follow-up after 1 month. Results: Total of 68 were enrolled in the study, out of which 63 completed the study. There was no difference observed at the pre-test in both the groups. After the intervention, there was a significant difference in the experimental group after post-test (U = 200.00, p = 0.0001). Adherence was improved in the experimental group. Conclusion: There is a need for clinical pharmacists in providing the patients with knowledge about long term disease management like psoriasis. The implement of specialty pharmacists in dermatological disorders is an excellent choice to address the unattended needs of the patient.

1 August 2019 in Journal of Young Pharmacists
Verified
Journal Article
Open access
LVLavanya Voora
Lavanya Voora
SSShastry C.S Shastry
Shastry C.S Shastry
RBRamesh Bhandari
Ramesh Bhandari
DSDegam Sukeerthi
Degam Sukeerthi
KRKala Bahadur Rawal
Kala Bahadur Rawal
SCSharad Chand
Sharad Chand

27 May 2023 in Indian Journal of Tuberculosis
Verified
Journal Article
Closed access
SSSnehi Shrestha
Snehi Shrestha
MAMubashir Angolkar
Mubashir Angolkar
ANAshwini Narasannavar
Ashwini Narasannavar
NANuha Al-Aghbari
Nuha Al-Aghbari
ARAkshata K. Ritti
Akshata K. Ritti
RBRamesh Bhandari
Ramesh Bhandari

1 February 2022 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
Raushan Kumar ChaudharyRaushan Kumar Chaudhary
Raushan Kumar Chaudhary
RBRamesh Bhandari
Ramesh Bhandari
BDBhavana Doshi
Bhavana Doshi
SKSatish S Karoli
Satish S Karoli
SMSowmya Spoorthi Marripalli
Sowmya Spoorthi Marripalli
MGM S Ganachari
M S Ganachari
Introduction: Pemphigus Vulgaris is a rare, noncommunicable, non-hereditary fatal autoimmune dermatological manifestation in which a painful blister initiates from the oral cavity. PRIDE complex stands for Papulopustules or paronychia, regulatory abnormality of hair and nails, itching, and dryness due to inhibition of EGFR. Both of these mucocutaneous manifestations are rare and are often caused by drugs. Case report: Our case reports 53-year-old patient presented with multiple crusted plaques, multiple hyperpigmented macules to patches, Solitary fluid-filled lesions on several parts of the body, and numerous erosions positive over buccal mucosa on initial follow up which was diagnosed as Pemphigus Vulgaris with PRIDE complex induced by Gefitinib. Management and outcome: The patient was treated with almost all possible treatment options, i.e., both steroids plus adjuvant therapy for pemphigus and antihistaminic, antibiotics, moisturizer, and lotions for PRIDE complex. The patient was initially admitted for infusion of the first dose of rituximab and later for management of flare-up condition and infusion of the second dose of rituximab infusion. Discussion: The complexity of the management of Pemphigus Vulgaris and PRIDE complex demands adequate monitoring of the patient's anti-cancerous therapy by clinical pharmacists, which can impact the clinical outcomes by providing pharmaceutical care and minimize the economic burden.